September 2022—Thermo Fisher Scientific launched its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus to identify genetic variants that resist common antiretroviral therapeutics.
The kit will analyze expanded targets associated with HIV drug resistance that include mutations in the integrase region of the pol gene on Applied Biosystems Sanger sequencing CE instrumentation and has been designed to offer broad group M subtype coverage. It is compatible with the recently launched Applied Biosystems MagMax Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 blood spots.
The kit is designed to support the detection of the UNAIDS 2030 95-95-95 HIV targets, which aim to have 95 percent of people living with HIV to be diagnosed, 95 percent who are diagnosed to be receiving treatment, and 95 percent of those on treatment to be virally suppressed.
Thermo Fisher Scientific, 781-622-1000